Replies to post #177215 on Biotech Values

[DewDiligence]

GILD—Not sure that even a minor advantage over Viread would be enough to fight generics after patent expiration. Will depend much on GILD's ability to switch patients before 2018 and then on how aggressive payers can be.

Agreed; however, I would still like you to quantify your expectation for GILD's share price if TAF is as good as Viread but not statsig better. T.i.a.